/
MIRM
$123.00-$0.77 (-0.62%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$7.5B
61M shares
52-week range
$47.89 – $125.39
97% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$105.37
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| Cost of revenue | $0 | $324.0K | $623.0K | $1.9M | $12.4M | $47.0M | $81.6M | $100.6M |
| Gross profit | $0 | −$324.0K | −$623.0K | $17.2M | $64.7M | $139.3M | $255.2M | $420.7M |
| Gross margin | — | — | — | 90.1% | 83.9% | 74.8% | 75.8% | 80.7% |
| R&D | $2.3M | $43.0M | $81.6M | $131.4M | $106.8M | $102.6M | $140.6M | $186.2M |
| Operating income | −$2.9M | −$54.7M | −$104.3M | −$173.4M | −$131.2M | −$109.2M | −$87.6M | −$22.1M |
| EBITDA | −$17.3M | −$52.2M | −$102.3M | −$65.4M | −$122.9M | −$136.5M | −$49.0M | $17.2M |
| Net income | −$17.3M | −$52.6M | −$103.3M | −$84.0M | −$135.7M | −$163.4M | −$87.9M | −$23.4M |
| Net margin | — | — | — | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| EPS (diluted) | -0.75 | -2.29 | -4.09 | -2.77 | -4.02 | -4.00 | -1.85 | -0.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $675M | $-15.65 | $-17.49–$-14.26 | 11 |
| 2027 | $812M | $-0.67 | $-7.99–$3.16 | 8 |
| 2028 | $1.1B | $2.35 | $0.63–$5.70 | 9 |
| 2029 | $1.4B | $5.42 | $5.01–$5.74 | 3 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Mirum Pharmaceuticals, Inc. Common Stock
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
www.mirumpharma.com- Employees
- 418
- IPO / List date
- Jul 18, 2019
- HQ
- FOSTER CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds MIRM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 582,085 | $53.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MIRM yet.
